查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球營運商篩檢市場
市場調查報告書
商品編碼
1380420

2023-2030 年全球營運商篩檢市場

Global Carrier Screening Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

預計全球帶因者篩檢市場在預測期內（2023-2030）將以 17.1% 的CAGR成長。市場的成長歸因於綜合測試的發展。 FirstGene 4 合 1 產前篩檢測試的推出是改善攜帶者篩檢和產前護理的更廣泛努力的一部分。為了滿足整個懷孕期間對整體遺傳見解不斷成長的需求，這項涵蓋產前健康和遺傳學多個方面的綜合測試正在幫助推動全球攜帶者篩檢市場。例如，2023 年 1 月，針對女性健康、腫瘤業務推出了 2023 年亮點產品。這家總部位於鹽湖城的公司繼續做好準備，在第三季度推出FirstGene 4 合1 產前篩檢測試，涵蓋無創產前篩檢、攜帶者篩檢、胎兒隱性狀態和胎兒-母體血液相容性。

細分市場前景

全球攜帶者篩檢市場按類型、醫療狀況、技術和最終用戶進行細分。根據類型，市場被細分為擴展疾病和目標疾病。依醫療狀況，市場分為血液疾病、肺病、神經病變等。根據技術，市場細分為 DNA 定序、聚合酶鍊式反應 (PCR)、微陣列等。此外，根據最終用戶，市場細分為醫院和診所、參考實驗室、政府和公共衛生項目等。 DNA 定序子類別預計將佔據技術領域的很大一部分市場佔有率。這是由於人類對遺傳性疾病的脆弱性增加。除了基因檢測知識的增加之外，由於該技術的使用增加，而不是任何道德問題，預計該市場也會成長。

預計血液學細分市場將在全球攜帶者篩檢市場中佔據相當大的佔有率

在醫療領域，血液學細分領域預計將在全球帶因者篩檢市場中佔據相當大的佔有率。此細分市場的成長歸因於對先進診斷工具的需求不斷成長。 Yumizen H500 和 H550 分析儀證明了診斷技術不斷發展，反映了醫療保健領域對更複雜、更有效的診斷工具日益成長的需求。由於血液分析儀的出現，血液學檢測過程應該變得更快、更準確，從而增強患者護理。例如，2022 年 7 月，HORIBA Medical 在其 Yumizen H500 和 H550 血液學產品系列中推出了新產品，即攜帶式桌上型血液分析儀，具有改進的功能、新的功能和額外的優勢。新型 Yumizen H500 和 H550 的吞吐量為每小時 60 次測試、40 個自動試管、連續加載、緊急手動模式以及透過多個分析模型和採樣運行樣品，旨在提供即時、全面的血液學報告。

區域展望

全球攜帶者篩檢市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於囊性纖維化等遺傳性疾病的高盛行率、市場參與者的增加以及該地區提供的檢測數量的大幅增加，預計北美將在全球市場中佔據顯著佔有率。地區。

預計亞太地區全球帶因者篩檢市場將以顯著的CAGR成長

在所有地區中，亞太地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區對基因檢測的需求和公眾意識的不斷成長。攜帶者篩檢方法的出現以及公眾對遺傳疾病的認知不斷提高，提高了對基因檢測服務，特別是攜帶者篩檢的需求。根據 BMC Medical Genetics 的數據，2022 年 11 月，出生缺陷是從出生時就存在的異常，可能導致嚴重死亡率、生產力下降和生活品質下降。在發展中國家，由於免疫接種、腹瀉和呼吸道感染控制以及醫療保健改善等傳染性和營養原因的減少，胎兒、新生兒、嬰兒和兒童死亡率的比例不斷上升。在西方，出生缺陷佔早期死亡率的 29.8%，佔慢性病的 29.2%。在印度，2010-2013年抽樣登記系統調查報告稱，先天畸形和遺傳性疾病分別佔兒童死亡率、嬰兒死亡率和新生兒死亡率的4.4%、4.6%和4.0%。預防出生缺陷，包括遺傳性疾病，是所有國家的優先事項，因為它們會造成社會恥辱、經濟負擔並降低生活品質，特別是在資源匱乏的國家。

市場參與者展望

服務全球攜帶者篩檢市場的主要公司包括： Congenica Ltd、Illumina, Inc.、Invitae Corp.、Myriad Genetics, Inc.、Natera Inc.等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2022 年1 月，Congenica 在2022 年阿拉伯健康大會上推出了一項新開發的行業首創產品，該產品結合了潛在父母的數位基因圖譜，進行徹底的攜帶者篩檢，以支持計劃生育決策。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球營運商篩選市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • DiaSorin SpA
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Eurofins Scientific
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Fulgent Genetics, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按類型分類的全球營運商篩選市場
    • 擴大攜帶者篩檢
    • 針對性疾病帶因者篩檢
  • 按醫療狀況分類的全球攜帶者篩檢市場
    • 血液學狀況
    • 肺部疾病
    • 神經系統疾病
    • 其他（家族性地中海熱 (FMF) 和脆性 X 症候群）
  • 按類型分類的全球營運商篩選市場
    • DNA定序
    • 聚合酶鍊式反應 (PCR)
    • 微陣列
    • 其他（次世代定序 (NGS)、篩選條件和直接面對消費者的測試）
  • 按最終用戶分類的全球營運商篩選市場
    • 醫院和診所
    • 參考實驗室
    • 政府和公共衛生計劃
    • 其他（製藥和生物型公司）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Ambry Genetics Corp.
  • Cepheid
  • Congenica Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Invitae Corp.
  • Laboratory Corporation of America (Labcorp)
  • MedGenome Inc
  • Myriad Genetics, Inc.
  • Natera Inc.
  • PerkinElmer AES
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific
Product Code: OMR2027829

Title: Global Carrier Screening Market Size, Share & Trends Analysis Report by Type (Expanded Carrier Screening, and Targeted Disease Carrier Screening), by Medical Condition (Hematological, Pulmonary, Neurological, and Others), by Technology (DNA Sequencing, Polymerase Chain Reaction (PCR), Microarrays, and Others), and by End User (Hospitals and Clinics, Reference Laboratories, Government and Public Health Programs, and Others)Forecast Period (2023-2030).

The global carrier screening market is anticipated to grow at a CAGR of 17.1% during the Forecast Period (2023-2030). The market's growth is attributed to development of comprehensive testing. The availability of the FirstGene 4-in-1 prenatal screening test is part of a wider effort to improve carrier screening and prenatal care. In response to the rising need for holistic genetic insights throughout pregnancy, this comprehensive test, that covers several aspects of prenatal health and genetics, is helping to boost the global carrier screening market. For instance, in January 2023, Highlights 2023 Product Launched for Women's Health, Oncology Businesses. The Salt Lake City-based company continues to grow prepared to introduce its FirstGene 4-in-1 prenatal screening test, that covers noninvasive prenatal screening, carrier screening, fetal recessive status, and feto-maternal blood compatibility, in Q3.

Segmental Outlook

The global carrier screening market is segmented on the type, medical condition, technology, and end-user. Based on the type, the market is sub-segmented into expanded, and targeted disease. Based on the medical condition, the market is sub-segmented into hematological, pulmonary, neurological, and others. Based on the technology, the market is sub-segmented into DNA sequencing, polymerase chain reaction (PCR), microarrays, and others. Further, on the basis of end-user, the market is sub-segmented into hospitals and clinics, reference laboratories, government and public health programs, and others. The DNA sequencing subcategory is expected to capture a significant portion of the market share within the technology segment. This is attributed to the increase in humanity's vulnerability to genetic disorders. The market is also anticipated to rise as a result of increased uses for the technology in addition to increased knowledge of genetic testing instead of any ethical problems.

The Hematological Sub-Segment is Anticipated to Hold a Considerable Share of the Global Carrier Screening Market

Among the medical condition, the hematological sub-segment is expected to hold a considerable share of the global carrier screening market. The segmental growth is attributed to the growing demand for advanced diagnostic tools. The Yumizen H500 & H550 analyzers are proof of the continuously evolving diagnostic technology that reflects the growing demand for more sophisticated and effective diagnostic tools in the healthcare sector. The hematological testing process should become faster and more accurate owing to blood analyzers, that can enhance patient care. For instance, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the portable benchtop hematology analyzers with improved functionality, new capabilities, and additional advantages. With a throughput of 60 tests per hour, 40 tubes of autonomy with continuous loading, urgent manual mode, and running samples through several analytical models and sampling, the new Yumizen H500 & H550 have been intended to offer an immediate and thorough hematological report.

Regional Outlook

The global carrier screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to a high prevalence of genetic disorders such as cystic fibrosis, a rise in market participants, and a significant rise in the number of tests offered in the region.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Carrier Screening Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for genetic testing and public awareness across the region. The availability of carrier screening methods and growing public awareness of genetic diseases have raised demand for genetic testing services, especially carrier screening. According to the BMC Medical Genetics, in November 2022, birth defects are abnormalities that are present from birth and can cause significant mortality, reduced productivity, and diminished quality of life. In developing countries, they have contributed to an increasing proportion of fetal, neonatal, infant and childhood mortality owing to a decline in infectious and nutritional causes such as immunizations, control of diarrheal and respiratory infections, and improved healthcare. In the West, birth defects account for 29.8% of early mortality and 29.2% of chronic problems. In India, the Sample Registration System Survey during 2010-2013 reported that congenital malformations and genetic disorders contributed 4.4, 4.6 and 4.0% to childhood mortality, infant mortality and neonatal mortality, respectively. The prevention of birth defects, including genetic disorders, is a priority in all countries, as they cause social stigmatization, economic burden, and diminish quality of life, especially in resource-poor countries.

Market Players Outlook

The major companies serving the global carrier screening market include: Congenica Ltd, Illumina, Inc., Invitae Corp., Myriad Genetics, Inc., Natera Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Congenica, launched a newly developed, industry-first offering at Arab Health 2022 that combines the digital genetic profiles of both potential parents for thorough carrier screening to support family planning decisions.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global carrier screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. DiaSorin S.p.A.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Eurofins Scientific
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Fulgent Genetics, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Carrier Screening Market by Type
    • 4.1.1. Expanded Carrier Screening
    • 4.1.2. Targeted Disease Carrier Screening
  • 4.2. Global Carrier Screening Market by Medical Condition
    • 4.2.1. Hematological Conditions
    • 4.2.2. Pulmonary Conditions
    • 4.2.3. Neurological Conditions
    • 4.2.4. Others (Familial Mediterranean Fever (FMF), and Fragile X Syndrome)
  • 4.3. Global Carrier Screening Market by Type
    • 4.3.1. DNA Sequencing
    • 4.3.2. Polymerase Chain Reaction (PCR)
    • 4.3.3. Microarrays
    • 4.3.4. Others (Next-Generation Sequencing (NGS), Screened Conditions, and Direct-to-Consumer Testing)
  • 4.4. Global Carrier Screening Market by End-User
    • 4.4.1. Hospitals and clinics
    • 4.4.2. Reference Laboratories
    • 4.4.3. Government and Public Health Programs
    • 4.4.4. Others (Pharmaceutical and Biotype Companies)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Ambry Genetics Corp.
  • 6.2. Cepheid
  • 6.3. Congenica Ltd.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. Illumina, Inc.
  • 6.6. Invitae Corp.
  • 6.7. Laboratory Corporation of America (Labcorp)
  • 6.8. MedGenome Inc
  • 6.9. Myriad Genetics, Inc.
  • 6.10. Natera Inc.
  • 6.11. PerkinElmer AES
  • 6.12. Quest Diagnostics Inc.
  • 6.13. Thermo Fisher Scientific

LIST OF TABLES

  • 1. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CARRIER SCREENING FOR OTHER MEDICAL CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION (PCR) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CARRIER SCREENING MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CARRIER SCREENING MARKET SHARE BY MEDICAL CONDITION, 2022 VS 2030 (%)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CARRIER SCREENING MARKET FOR OTHER APPLICATIONS SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CARRIER SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CARRIER SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 20. US CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)